Effect of Human Amniotic Fluid Stem Cells on Kidney Function in a Model of Chronic Kidney Disease
- Authors
- George, Sunil K.; Abolbashari, Mehran; Kim, Tae-Hyoung; Zhang, Chao; Allickson, Julie; Jackson, John D.; Lee, Sang Jin; Ko, In Kap; Atala, Anthony; Yoo, James J.
- Issue Date
- Nov-2019
- Publisher
- MARY ANN LIEBERT, INC
- Keywords
- stem cell therapy; amniotic fluid; chronic kidney disease; kidney regeneration
- Citation
- TISSUE ENGINEERING PART A, v.25, no.21-22, pp 1493 - 1503
- Pages
- 11
- Journal Title
- TISSUE ENGINEERING PART A
- Volume
- 25
- Number
- 21-22
- Start Page
- 1493
- End Page
- 1503
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/38658
- DOI
- 10.1089/ten.tea.2018.0371
- ISSN
- 1937-3341
1937-335X
- Abstract
- Kidney disease is a major medical problem globally. Chronic kidney disease (CKD) is a progressive loss of kidney function. It causes accumulation of waste and fluid in the body, eventually resulting in kidney failure as well as damaging other organs. Although dialysis and kidney transplantation have been used as primary treatments for renal disease, dialysis does not restore full renal function, and there is a shortage of donor kidneys for transplantation. Recent advances in cell-based therapies have offered a means to augment and restore renal function. Various types of cells have been tested to evaluate their therapeutic effects on injured kidneys. Among various types of cells, amniotic fluid stem cells (AFSCs) share advantages of both embryonic and adult stem cells, such as pluripotent activity, remarkable plasticity, and immunomodulatory effects, which may allow their future therapeutic use as an "off-the-shelf" cell source. AFSC presents advantages of both conventional pluripotent and adult stem cells, such as pluripotent activity, remarkable plasticity, and immunomodulatory effects. This study demonstrates that administration of human-derived AFSC facilitates functional and structural improvement in a rat model of CKD, and suggests that cell therapy with AFSC has potential as a therapeutic strategy to recover renal function in patients with CKD. Impact Statement Patients with chronic kidney disease (CKD) have limited treatment options, and renal transplantation is the only definitive treatment method that restores kidney function. However, challenges associated with transplantation, including donor organ shortage, rejection, and life-long immunosuppression, remain a problem. Recently, stem cell-based therapies have been proposed as an alternative approach to augment and restore renal function. In this study, we used human-derived amniotic fluid stem cells (AFSCs) to treat CKD in a rat model and demonstrated that AFSC treatment facilitated positive effects in terms of improvements of renal function.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/38658)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.